Evidence map›Paper›PMID 37818930›Full record

ArticleJournal of medical economics

A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand.

Ratthanon Prasitwarachot, Kednapa Thavorn, Chanthawat Patikorn, Somkiat Wattanasirichaigoon, Suthat Rungruanghiranya, Araya Thongphiew, Nathorn Chaiyakunapruk

Abstract readMulticenter Study
In one paragraph

Article in Journal of medical economics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ratthanon PrasitwarachotDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-5244-8489
Kednapa ThavornOttawa Hospital Research Institute, Ottawa Hospital, Ottawa, Canada.ORCID 0000-0003-4738-8447
Chanthawat PatikornDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-3502-4718
Somkiat WattanasirichaigoonDivision of Information Technology Management, Faculty of Engineering, Mahidol University, Nakhon Pathom, Thailand.
Suthat RungruanghiranyaThai Health Professional Alliance Against Tobacco, Bangkok, Thailand.
Araya ThongphiewThai Health Professional Alliance Against Tobacco, Bangkok, Thailand.
Nathorn ChaiyakunaprukDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-4572-8794

Funding

CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
NCATS NIH HHS UM1 TR004409
6 · The paper itself

Abstract

aimsThailand's national smoking cessation services (FAH-SAI clinics) were founded in 2010. A cost-effectiveness analysis (CEA) is needed to inform policymakers of the allocation and prioritization of the limited budget to maximize the value for money of reimbursing these services. Chronic obstructive pulmonary disease (COPD) patients would benefit from smoking cessation services. Therefore, this study aimed to assess the cost-effectiveness of these multidisciplinary services compared to the usual care among COPD patients in Thailand from a societal perspective.

methodsWe conducted a CEA from a societal perspective using a Markov model to simulate lifetime costs and quality-adjusted life years (QALYs) gained by each smoking cessation intervention over the patient's lifetime. We derived the effectiveness of the smoking cessation services from a multicenter, longitudinal study of smoking cessation services in Thailand and estimated the natural quit rate, transition probabilities, health utility, and cost data from the published literature. Costs and outcomes were discounted at 3%. Sensitivity analyses were performed.

resultsCompared to the usual care, FAH-SAI clinics were associated with higher costs (4,207 THB (US$133)) and improved QALYs (0.11), with an incremental cost-effectiveness ratio of 37,675 THB/QALY (US$1,187/QALY). The effectiveness of FAH-SAI clinics was a key driver of the cost-effectiveness results. At the willingness-to-pay (WTP) threshold of 160,000 THB (US$5,042) per QALY gained, the probability of being cost-effective was 96.5%.

conclusionsFAH-SAI clinics were cost-effective under Thailand's WTP threshold. Our results could inform policymakers in allocating resources to support smoking cessation services for COPD patients in Thailand.

Indexed as

Pulmonary Disease, Chronic ObstructiveSmoking CessationCost-Benefit AnalysisCost-Effectiveness AnalysisHumansLongitudinal StudiesQuality-Adjusted Life YearsThailandchronic obstructive pulmonary diseaseCost-effectiveness analysiseconomic evaluationII1I15I18smoking cessationThailand

Identifiers

PMID37818930
PMCPMC11294018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.